https://www.nasdaq.com/press-release/biogen-exercises-option-with-ionis-to-develop-and-commercialize-investigational-aso-0
https://www.nasdaq.com/press-release/biogen-exercises-option-with-ionis-to-develop-and-commercialize-investigational-aso-1
https://www.nasdaq.com/press-release/biogen-exercises-option-with-ionis-to-develop-and-commercialize-investigational-aso
https://www.nasdaq.com/press-release/investigational-alzheimers-disease-therapy-lecanemab-granted-fda-fast-track
https://www.nasdaq.com/press-release/japans-first-committee-on-new-drugs-of-the-pharmaceutical-affairs-and-food-sanitation
https://www.nasdaq.com/press-release/japans-first-committee-on-new-drugs-of-the-pharmaceutical-affairs-and-food-0
https://www.nasdaq.com/press-release/biogen-announces-reduced-price-for-aduhelmr-to-improve-access-for-patients-with-early
https://www.nasdaq.com/press-release/biogen-announces-reduced-price-for-aduhelmr-to-improve-access-for-patients-with-0
https://www.nasdaq.com/press-release/update-on-regulatory-submission-for-aducanumab-in-the-european-union-2021-12-17-0
https://www.nasdaq.com/press-release/update-on-regulatory-submission-for-aducanumab-in-the-european-union-2021-12-17
https://www.nasdaq.com/press-release/update-on-the-phase-4-confirmatory-study-of-aduhelmr-2021-12-16
https://www.nasdaq.com/press-release/update-on-the-phase-4-confirmatory-study-of-aduhelmr-2021-12-16-0
https://www.nasdaq.com/press-release/biogen-and-therapanacea-announce-new-collaboration-with-the-potential-to-advance
https://www.nasdaq.com/press-release/biogen-and-therapanacea-announce-new-collaboration-with-the-potential-to-advance-0
https://www.nasdaq.com/press-release/sage-therapeutics-and-biogen-announce-new-analyses-from-the-landscape-clinical
https://www.nasdaq.com/press-release/sage-therapeutics-and-biogen-announce-positive-one-year-zuranolone-50-mg-data-in-the
https://www.nasdaq.com/press-release/update-on-regulatory-review-of-aducanumab-in-the-european-union-2021-11-17
https://www.nasdaq.com/press-release/update-on-regulatory-review-of-aducanumab-in-the-european-union-2021-11-17-0
https://www.nasdaq.com/press-release/the-european-commission-grants-marketing-authorization-for-vumerityr-diroximel-0
https://www.nasdaq.com/press-release/the-european-commission-grants-marketing-authorization-for-vumerityr-diroximel
https://www.nasdaq.com/press-release/biogen-announces-alfred-w.-sandrock-jr.-to-retire-as-head-of-research-development
https://www.nasdaq.com/press-release/biogen-announces-alfred-w.-sandrock-jr.-to-retire-as-head-of-research-development-0
https://www.nasdaq.com/press-release/biogen-sets-industry-record-with-recognition-on-dow-jones-sustainability-world-0
https://www.nasdaq.com/press-release/biogen-sets-industry-record-with-recognition-on-dow-jones-sustainability-world-index
https://www.nasdaq.com/press-release/new-phase-3-data-show-positive-correlation-between-aduhelmtm-treatment-effect-on-0
https://www.nasdaq.com/press-release/new-phase-3-data-show-positive-correlation-between-aduhelmtm-treatment-effect-on
https://www.nasdaq.com/press-release/introduction-of-first-of-a-kind-plasma-based-biomarker-screening-to-facilitate
https://www.nasdaq.com/press-release/eisai-presents-new-analysis-of-lecanemab-clinical-efficacy-results-from-phase-2b
https://www.nasdaq.com/press-release/eisai-presents-late-breaker-updates-on-lecanemab-clinical-biomarker-and-safety-data
https://www.nasdaq.com/press-release/biogen-announces-late-breakers-and-additional-new-data-presentations-at-the-2021
https://www.nasdaq.com/press-release/biogen-announces-late-breakers-and-additional-new-data-presentations-at-the-2021-0
https://www.nasdaq.com/press-release/sage-therapeutics-and-biogen-announce-plans-to-submit-a-new-drug-application-nda-for
https://www.nasdaq.com/press-release/biogen-announces-topline-results-from-the-tofersen-phase-3-study-and-its-open-label
https://www.nasdaq.com/press-release/biogen-announces-topline-results-from-the-tofersen-phase-3-study-and-its-open-label-0
https://www.nasdaq.com/press-release/topline-results-from-tofersen-phase-3-study-and-its-open-label-extension-in-sod1-als
https://www.nasdaq.com/press-release/topline-results-from-tofersen-phase-3-study-and-its-open-label-extension-in-sod1-0
https://www.nasdaq.com/press-release/new-data-at-ectrims-2021-highlight-biogens-focus-on-patient-centered-outcomes-and
https://www.nasdaq.com/press-release/new-data-at-ectrims-2021-highlight-biogens-focus-on-patient-centered-outcomes-and-0
https://www.nasdaq.com/press-release/new-ms-paths-data-at-ectrims-2021-confirm-biogens-disease-modifying-therapies-do-0
https://www.nasdaq.com/press-release/new-ms-paths-data-at-ectrims-2021-confirm-biogens-disease-modifying-therapies-do-not
https://www.nasdaq.com/press-release/sage-therapeutics-and-biogen-announce-consistent-clinically-meaningful-data-for
https://www.nasdaq.com/press-release/eisai-initiates-rolling-submission-to-the-u.s.-fda-for-biologics-license-application
https://www.nasdaq.com/press-release/biogen-rd-day-to-provide-overview-of-diversified-pipeline-and-capabilities-with-0
https://www.nasdaq.com/press-release/biogen-rd-day-to-provide-overview-of-diversified-pipeline-and-capabilities-with
https://www.nasdaq.com/press-release/fda-approves-samsung-bioepis-and-biogens-byooviztm-sb11-lucentisr-biosimilar
https://www.nasdaq.com/press-release/fda-approves-samsung-bioepis-and-biogens-byooviztm-sb11-lucentisr-biosimilar-0
https://www.nasdaq.com/press-release/chmp-recommends-vumerityr-diroximel-fumarate-for-approval-in-the-european-union-as-a
https://www.nasdaq.com/press-release/chmp-recommends-vumerityr-diroximel-fumarate-for-approval-in-the-european-union-as-0
https://www.nasdaq.com/press-release/biogen-announces-positive-topline-results-from-phase-2-convey-study-in-small-fiber-0
https://www.nasdaq.com/press-release/biogen-announces-positive-topline-results-from-phase-2-convey-study-in-small-fiber
https://www.nasdaq.com/press-release/biogen-plans-to-initiate-phase-3b-study-evaluating-potential-benefit-of-a-higher-dose
https://www.nasdaq.com/press-release/biogen-plans-to-initiate-phase-3b-study-evaluating-potential-benefit-of-a-higher-0
https://www.nasdaq.com/press-release/biogen-announces-results-from-phase-3b-nova-study-evaluating-every-six-week-dosing
https://www.nasdaq.com/press-release/biogen-announces-results-from-phase-3b-nova-study-evaluating-every-six-week-dosing-0
https://www.nasdaq.com/press-release/late-breaking-aaic-presentation-explores-potential-clinical-effects-of-lecanemab
https://www.nasdaq.com/press-release/biogen-and-eisai-announce-design-of-aduhelm-icare-ad-us-study-the-first-real-world-0
https://www.nasdaq.com/press-release/biogen-and-eisai-announce-design-of-aduhelm-icare-ad-us-study-the-first-real-world
https://www.nasdaq.com/press-release/biogen-and-ionis-report-positive-topline-clinical-data-on-investigational-alzheimers
https://www.nasdaq.com/press-release/biogen-and-eisai-announce-aduhelmtm-aducanumab-avwa-data-presentations-at-0
https://www.nasdaq.com/press-release/biogen-and-eisai-announce-aduhelmtm-aducanumab-avwa-data-presentations-at-alzheimers
https://www.nasdaq.com/press-release/biogen-to-present-data-from-aduhelm-and-alzheimers-disease-portfolio-at-2021-0
https://www.nasdaq.com/press-release/biogen-to-present-data-from-aduhelm-and-alzheimers-disease-portfolio-at-2021
https://www.nasdaq.com/press-release/an-open-letter-to-the-alzheimers-disease-community-from-our-head-of-research-and-0
https://www.nasdaq.com/press-release/an-open-letter-to-the-alzheimers-disease-community-from-our-head-of-research-and
https://www.nasdaq.com/press-release/mirimus-inc.-forms-strategic-collaboration-with-biogen-to-develop-rnai-based
https://www.nasdaq.com/press-release/biogen-and-innocare-announce-license-and-collaboration-agreement-for-orelabrutinib-0
https://www.nasdaq.com/press-release/biogen-and-innocare-announce-license-and-collaboration-agreement-for-orelabrutinib-an
https://www.nasdaq.com/press-release/collaboration-between-abbvie-biogen-and-pfizer-creates-worlds-largest-browsable
https://www.nasdaq.com/press-release/collaboration-between-abbvie-biogen-and-pfizer-creates-worlds-largest-browsable-0
https://www.nasdaq.com/press-release/fda-approves-updated-aduhelmtm-prescribing-information-to-emphasize-population-0
https://www.nasdaq.com/press-release/fda-approves-updated-aduhelmtm-prescribing-information-to-emphasize-population
https://www.nasdaq.com/press-release/enel-x-collaborates-with-biogen-to-electrify-take-home-vehicle-fleet-in-north-america
https://www.nasdaq.com/press-release/enel-x-collaborates-with-biogen-to-electrify-take-home-vehicle-fleet-in-north-0
https://www.nasdaq.com/press-release/samsung-bioepis-and-biogen-receive-positive-chmp-opinion-for-ranibizumab-biosimilar
https://www.nasdaq.com/press-release/samsung-bioepis-and-biogen-receive-positive-chmp-opinion-for-ranibizumab-biosimilar-0
https://www.nasdaq.com/press-release/eisai-and-biogen-inc.-announce-u.s.-fda-grants-breakthrough-therapy-designation-for
https://www.nasdaq.com/press-release/kenan-fellows-program-and-biogen-foundation-collaborate-to-advance-workforce
https://www.nasdaq.com/press-release/biogen-announces-first-patient-dosed-in-phase-3-systemic-lupus-erythematosus-study
https://www.nasdaq.com/press-release/biogen-announces-first-patient-dosed-in-phase-3-systemic-lupus-erythematosus-study-0
https://www.nasdaq.com/press-release/biogen-announces-topline-results-from-phase-2-study-of-gosuranemab-an-anti-tau
https://www.nasdaq.com/press-release/biogen-announces-topline-results-from-phase-2-study-of-gosuranemab-an-anti-tau-0
https://www.nasdaq.com/press-release/sage-therapeutics-and-biogen-announce-positive-pivotal-phase-3-results-for-zuranolone
https://www.nasdaq.com/press-release/sage-therapeutics-and-biogen-announce-positive-pivotal-phase-3-results-for-1
https://www.nasdaq.com/press-release/sage-therapeutics-and-biogen-announce-positive-pivotal-phase-3-results-for-0
https://www.nasdaq.com/press-release/biogen-announces-topline-results-from-phase-3-gene-therapy-study-in-choroideremia-0
https://www.nasdaq.com/press-release/biogen-announces-topline-results-from-phase-3-gene-therapy-study-in-choroideremia
https://www.nasdaq.com/press-release/biogen-announces-investor-day-on-september-21-2021-2021-06-10
https://www.nasdaq.com/press-release/new-data-at-cure-sma-2021-highlight-the-long-term-efficacy-of-spinrazar-nusinersen-0
https://www.nasdaq.com/press-release/new-data-at-cure-sma-2021-highlight-the-long-term-efficacy-of-spinrazar-nusinersen
https://www.nasdaq.com/press-release/biogen-and-eisai-launch-multiple-initiatives-to-help-patients-with-alzheimers-0
https://www.nasdaq.com/press-release/biogen-and-eisai-launch-multiple-initiatives-to-help-patients-with-alzheimers-disease
https://www.nasdaq.com/press-release/fda-grants-accelerated-approval-for-aduhelmtm-as-the-first-and-only-alzheimers-0
https://www.nasdaq.com/press-release/fda-grants-accelerated-approval-for-aduhelmtm-as-the-first-and-only-alzheimers
https://www.nasdaq.com/press-release/biogen-and-bio-thera-announce-positive-results-from-phase-3-study-of-bat1806-a-0
https://www.nasdaq.com/press-release/biogen-and-bio-thera-announce-positive-results-from-phase-3-study-of-bat1806-a
https://www.nasdaq.com/press-release/biogen-and-ginkgo-bioworks-announce-collaboration-and-license-agreement-to-develop-0
https://www.nasdaq.com/press-release/biogen-and-ginkgo-bioworks-announce-collaboration-and-license-agreement-to-develop
https://www.nasdaq.com/press-release/swissmedic-grants-good-manufacturing-practice-multi-product-license-to-biogen-0
https://www.nasdaq.com/press-release/swissmedic-grants-good-manufacturing-practice-multi-product-license-to-biogen
https://www.nasdaq.com/press-release/biogen-announces-topline-results-from-phase-2-3-gene-therapy-study-for-xlrp-2021-05
https://www.nasdaq.com/press-release/biogen-announces-topline-results-from-phase-2-3-gene-therapy-study-for-xlrp-2021-05-0
https://www.nasdaq.com/press-release/biogen-and-envisagenics-announce-collaboration-to-advance-rna-splicing-research-2021
https://www.nasdaq.com/press-release/biogen-and-envisagenics-announce-collaboration-to-advance-rna-splicing-research-0
https://www.nasdaq.com/press-release/biogen-announces-exercise-of-option-to-acquire-the-investigational-drug-tms-007-for-0
https://www.nasdaq.com/press-release/biogen-announces-exercise-of-option-to-acquire-the-investigational-drug-tms-007-for
https://www.nasdaq.com/press-release/biogen-and-capsigen-announce-collaboration-to-discover-and-develop-novel-aav-0
https://www.nasdaq.com/press-release/biogen-and-capsigen-announce-collaboration-to-discover-and-develop-novel-aav-capsids
https://www.nasdaq.com/press-release/biogen-provides-regulatory-update-on-the-supplemental-biologic-license-application-0
https://www.nasdaq.com/press-release/biogen-provides-regulatory-update-on-the-supplemental-biologic-license-application
https://www.nasdaq.com/press-release/biogen-releases-2020-year-in-review-demonstrating-its-commitment-to-transparency-and
https://www.nasdaq.com/press-release/biogen-releases-2020-year-in-review-demonstrating-its-commitment-to-transparency-0
https://www.nasdaq.com/press-release/18-month-pre-specified-analysis-showing-consistent-reduction-in-clinical-outcome
https://www.nasdaq.com/press-release/biogen-advances-leading-research-in-spinal-muscular-atrophy-sma-with-new-data-at-aan
https://www.nasdaq.com/press-release/biogen-advances-leading-research-in-spinal-muscular-atrophy-sma-with-new-data-at-0
https://www.nasdaq.com/press-release/new-data-at-aan-2021-from-across-biogens-ms-portfolio-demonstrate-positive-impact-of
https://www.nasdaq.com/press-release/new-data-at-aan-2021-from-across-biogens-ms-portfolio-demonstrate-positive-impact-0
https://www.nasdaq.com/press-release/biogen-grows-presence-in-china-with-the-approval-of-tecfiderar-dimethyl-fumarate-for
https://www.nasdaq.com/press-release/biogen-grows-presence-in-china-with-the-approval-of-tecfiderar-dimethyl-fumarate-0
https://www.nasdaq.com/press-release/biogen-to-present-trial-design-of-aducanumab-embark-re-dosing-study-in-poster-session
https://www.nasdaq.com/press-release/biogen-to-present-trial-design-of-aducanumab-embark-re-dosing-study-in-poster-0
https://www.nasdaq.com/press-release/sage-therapeutics-and-biogen-announce-sage-324-phase-2-placebo-controlled-kinetic
https://www.nasdaq.com/press-release/biogen-announces-two-new-nominees-for-election-to-board-of-directors-2021-04-09-0
https://www.nasdaq.com/press-release/biogen-announces-two-new-nominees-for-election-to-board-of-directors-2021-04-09
https://www.nasdaq.com/press-release/biogen-and-bio-thera-solutions-announce-commercialization-and-license-agreement-for
https://www.nasdaq.com/press-release/biogen-and-bio-thera-solutions-announce-commercialization-and-license-agreement-for-0
https://www.nasdaq.com/press-release/the-european-commission-grants-marketing-authorization-for-new-subcutaneous
https://www.nasdaq.com/press-release/the-european-commission-grants-marketing-authorization-for-new-subcutaneous-0
https://www.nasdaq.com/press-release/biogen-announces-plans-to-build-a-new-state-of-the-art-gene-therapy-manufacturing-0
https://www.nasdaq.com/press-release/biogen-announces-plans-to-build-a-new-state-of-the-art-gene-therapy-manufacturing
https://www.nasdaq.com/press-release/life-science-cares-and-biogen-foundation-help-launch-food-for-frees-just-eats-0
https://www.nasdaq.com/press-release/life-science-cares-and-biogen-foundation-help-launch-food-for-frees-just-eats-program
https://www.nasdaq.com/press-release/biogen-announces-the-expiration-date-results-of-its-cash-tender-offer-2021-02-11-0
https://www.nasdaq.com/press-release/biogen-announces-the-expiration-date-results-of-its-cash-tender-offer-2021-02-11
https://www.nasdaq.com/press-release/biogen-announces-the-expiration-date-results-of-its-private-exchange-offer-2021-02-11
https://www.nasdaq.com/press-release/biogen-announces-the-expiration-date-results-of-its-private-exchange-offer-2021-02-0
https://www.nasdaq.com/press-release/biogen-and-labcentral-award-two-golden-tickets-to-local-and-innovative-science
https://www.nasdaq.com/press-release/biogen-announces-the-pricing-terms-of-its-cash-tender-offer-2021-02-10-0
https://www.nasdaq.com/press-release/biogen-announces-the-pricing-terms-of-its-cash-tender-offer-2021-02-10
https://www.nasdaq.com/press-release/biogen-announces-the-pricing-terms-of-its-private-exchange-offer-2021-02-10
https://www.nasdaq.com/press-release/biogen-announces-the-pricing-terms-of-its-private-exchange-offer-2021-02-10-0
https://www.nasdaq.com/press-release/biogen-announces-cash-tender-offer-for-5.200-senior-notes-due-2045-open-to-certain-0
https://www.nasdaq.com/press-release/biogen-announces-cash-tender-offer-for-5.200-senior-notes-due-2045-open-to-certain
https://www.nasdaq.com/press-release/biogen-announces-private-exchange-offer-for-5.200-senior-notes-due-2045-open-to-0
https://www.nasdaq.com/press-release/biogen-announces-private-exchange-offer-for-5.200-senior-notes-due-2045-open-to
https://www.nasdaq.com/press-release/biogen-announces-fda-approval-of-plegridyr-peginterferon-beta-1a-intramuscular-0
https://www.nasdaq.com/press-release/biogen-announces-fda-approval-of-plegridyr-peginterferon-beta-1a-intramuscular
https://www.nasdaq.com/press-release/biogen-and-eisai-announce-fdas-3-month-extension-of-review-period-for-the-biologics-0
https://www.nasdaq.com/press-release/biogen-and-eisai-announce-fdas-3-month-extension-of-review-period-for-the-biologics
https://www.nasdaq.com/press-release/biogen-to-launch-pioneering-study-to-develop-digital-biomarkers-of-cognitive-health
https://www.nasdaq.com/press-release/biogen-to-launch-pioneering-study-to-develop-digital-biomarkers-of-cognitive-health-0
https://www.nasdaq.com/press-release/atalanta-therapeutics-launches-with-%24110-million-to-pioneer-rnai-therapeutics-for
https://www.nasdaq.com/press-release/biogen-announces-first-patient-treated-in-respond-study-evaluating-benefit-of-0
https://www.nasdaq.com/press-release/biogen-announces-first-patient-treated-in-respond-study-evaluating-benefit-of
https://www.nasdaq.com/press-release/vigeneron-signs-global-collaboration-agreement-for-ophthalmic-gene-therapy
https://www.nasdaq.com/press-release/the-european-commission-grants-marketing-authorization-for-plegridyr-peginterferon
https://www.nasdaq.com/press-release/the-european-commission-grants-marketing-authorization-for-plegridyr-peginterferon-0
https://www.nasdaq.com/press-release/aprinoia-therapeutics-established-collaboration-on-tau-pet-imaging-tracer-development
https://www.nasdaq.com/press-release/biogen-files-new-drug-application-for-aducanumab-in-japan-2020-12-09-0
https://www.nasdaq.com/press-release/biogen-files-new-drug-application-for-aducanumab-in-japan-2020-12-09
https://www.nasdaq.com/press-release/new-coalition-aims-to-close-the-opportunity-gap-in-bioscience-2020-12-03
https://www.nasdaq.com/press-release/biogen-and-sage-therapeutics-announce-global-collaboration-to-develop-and
https://www.nasdaq.com/press-release/biogen-and-sage-therapeutics-announce-global-collaboration-to-develop-and-0
https://www.nasdaq.com/press-release/biogen-and-sage-therapeutics-announce-global-collaboration-to-develop-and-1
https://www.nasdaq.com/press-release/samsung-bioepis-and-biogen-announce-fda-filing-acceptance-of-sb11-a-proposed
https://www.nasdaq.com/press-release/samsung-bioepis-and-biogen-announce-fda-filing-acceptance-of-sb11-a-proposed-0
https://www.nasdaq.com/press-release/biogen-ranked-1-biotechnology-company-by-dow-jones-sustainability-world-index-for-0
https://www.nasdaq.com/press-release/biogen-ranked-1-biotechnology-company-by-dow-jones-sustainability-world-index-for-an
https://www.nasdaq.com/press-release/update-on-fda-advisory-committees-meeting-on-aducanumab-in-alzheimers-disease-2020-11
https://www.nasdaq.com/press-release/update-on-fda-advisory-committees-meeting-on-aducanumab-in-alzheimers-disease-2020-0
https://www.nasdaq.com/press-release/biogen-to-present-positive-phase-2-systemic-lupus-erythematosus-data-at-american
https://www.nasdaq.com/press-release/biogen-to-present-positive-phase-2-systemic-lupus-erythematosus-data-at-american-0
https://www.nasdaq.com/press-release/european-medicines-agency-accepts-biogens-aducanumab-marketing-authorization
https://www.nasdaq.com/press-release/european-medicines-agency-accepts-biogens-aducanumab-marketing-authorization-0
https://www.nasdaq.com/press-release/abarca-details-first-value-based-agreement-for-medicaid-members-prescribed-biogen
https://www.nasdaq.com/press-release/scribe-therapeutics-to-collaborate-with-biogen-to-develop-crispr-based-genetic
https://www.nasdaq.com/press-release/samsung-bioepis-and-biogen-announce-ema-filing-acceptance-of-sb11-a-proposed
https://www.nasdaq.com/press-release/samsung-bioepis-and-biogen-announce-ema-filing-acceptance-of-sb11-a-proposed-0
https://www.nasdaq.com/press-release/biogen-to-invest-%24250-million-in-a-20-year-initiative-to-eliminate-its-use-of-fossil
https://www.nasdaq.com/press-release/biogen-to-invest-%24250-million-in-a-20-year-initiative-to-eliminate-its-use-of-0
https://www.nasdaq.com/press-release/new-data-at-actrims-ectrims-meeting-showcase-safety-and-efficacy-of-biogens-industry
https://www.nasdaq.com/press-release/new-data-at-actrims-ectrims-meeting-showcase-safety-and-efficacy-of-biogens-0
https://www.nasdaq.com/press-release/new-biogen-data-presented-at-actrims-ectrims-advance-understanding-of-clinical-and-0
https://www.nasdaq.com/press-release/new-biogen-data-presented-at-actrims-ectrims-advance-understanding-of-clinical-and
https://www.nasdaq.com/press-release/oneunited-bank-fintech-pioneer-announces-%2410-million-deposit-by-biogen-to-support
https://www.nasdaq.com/press-release/fda-accepts-biogens-aducanumab-biologics-license-application-for-alzheimers-disease-0
https://www.nasdaq.com/press-release/fda-accepts-biogens-aducanumab-biologics-license-application-for-alzheimers-disease
https://www.nasdaq.com/press-release/biogen-and-denali-to-collaborate-on-lrrk2-program-for-parkinsons-disease-and-certain
https://www.nasdaq.com/press-release/biogen-and-denali-to-collaborate-on-lrrk2-program-for-parkinsons-disease-and-0
https://www.nasdaq.com/press-release/biogen-to-present-data-at-virtual-2020-alzheimers-association-international
https://www.nasdaq.com/press-release/biogen-to-present-data-at-virtual-2020-alzheimers-association-international-0
https://www.nasdaq.com/press-release/biogen-names-michael-mcdonnell-as-executive-vice-president-and-chief-financial
https://www.nasdaq.com/press-release/biogen-names-michael-mcdonnell-as-executive-vice-president-and-chief-financial-0
https://www.nasdaq.com/press-release/biogen-plans-to-initiate-phase-4-study-evaluating-benefit-of-spinrazar-nusinersen-0
https://www.nasdaq.com/press-release/biogen-plans-to-initiate-phase-4-study-evaluating-benefit-of-spinrazar-nusinersen-in
https://www.nasdaq.com/press-release/initiation-of-new-phase-iii-clinical-study-ahead-3-45-of-ban2401-preclinical
https://www.nasdaq.com/press-release/the-new-england-journal-of-medicine-publishes-final-results-from-phase-1-2-study-of
https://www.nasdaq.com/press-release/the-new-england-journal-of-medicine-publishes-final-results-from-phase-1-2-study-of-0
https://www.nasdaq.com/press-release/biogen-completes-submission-of-biologics-license-application-to-fda-for-aducanumab-0
https://www.nasdaq.com/press-release/biogen-completes-submission-of-biologics-license-application-to-fda-for-aducanumab-as
https://www.nasdaq.com/press-release/new-results-from-landmark-nurture-study-show-that-pre-symptomatic-sma-patients-0
https://www.nasdaq.com/press-release/new-results-from-landmark-nurture-study-show-that-pre-symptomatic-sma-patients
https://www.nasdaq.com/press-release/biogen-presents-positive-phase-2-cutaneous-lupus-erythematosus-cle-data-at-european-0
https://www.nasdaq.com/press-release/biogen-presents-positive-phase-2-cutaneous-lupus-erythematosus-cle-data-at-european-e
https://www.nasdaq.com/press-release/biogen-and-mit-launch-new-virtual-learning-lab-for-high-school-students-0
https://www.nasdaq.com/press-release/biogen-and-mit-launch-new-virtual-learning-lab-for-high-school-students-historically
https://www.nasdaq.com/press-release/new-data-at-aan-showcase-biogens-commitment-to-advancing-innovation-in-ms-2020-05-19
https://www.nasdaq.com/press-release/new-data-at-aan-showcase-biogens-commitment-to-advancing-innovation-in-ms-2020-05-0
https://www.nasdaq.com/press-release/new-spinrazar-nusinersen-data-reinforce-sustained-efficacy-and-longer-term-safety
https://www.nasdaq.com/press-release/new-spinrazar-nusinersen-data-reinforce-sustained-efficacy-and-longer-term-safety-0
https://www.nasdaq.com/press-release/biogen-prices-%243.0-billion-of-senior-unsecured-notes-2020-04-27
https://www.nasdaq.com/press-release/biogen-prices-%243.0-billion-of-senior-unsecured-notes-2020-04-27-0
https://www.nasdaq.com/press-release/biogen-releases-2019-corporate-responsibility-report-demonstrating-continuous
https://www.nasdaq.com/press-release/biogen-releases-2019-corporate-responsibility-report-demonstrating-continuous-0
https://www.nasdaq.com/press-release/biogen-broad-institute-of-mit-and-harvard-partners-healthcare-launch-consortium-to-0
https://www.nasdaq.com/press-release/biogen-broad-institute-of-mit-and-harvard-partners-healthcare-launch-consortium-to
https://www.nasdaq.com/press-release/biogen-announces-first-patient-treated-with-higher-dose-of-spinrazar-nusinersen-in
https://www.nasdaq.com/press-release/biogen-announces-first-patient-treated-with-higher-dose-of-spinrazar-nusinersen-in-0
https://www.nasdaq.com/press-release/biogen-foundation-commits-%2410-million-to-support-covid-19-relief-efforts-in-the-u.s.
https://www.nasdaq.com/press-release/biogen-and-sangamo-announce-global-collaboration-to-develop-gene-regulation-therapies
https://www.nasdaq.com/press-release/biogen-to-acquire-novel-clinical-stage-asset-with-application-in-alzheimers-disease
https://www.nasdaq.com/press-release/behind-the-seizurer-program-further-expands-access-to-genetic-testing-for-children-to
https://www.nasdaq.com/press-release/biogen-reports-top-line-results-from-phase-2-study-in-progressive-supranuclear-palsy
https://www.nasdaq.com/press-release/biogen-announces-positive-phase-2-study-results-for-cutaneous-lupus-erythematosus-cle
https://www.nasdaq.com/press-release/biogen-presents-data-demonstrating-improved-gastrointestinal-tolerability-with
https://www.nasdaq.com/press-release/biogen-announces-enrollment-completion-of-global-phase-3-gene-therapy-study-for-an
https://www.nasdaq.com/press-release/alkermes-announces-receipt-of-%24150-million-milestone-payment-from-biogen-related-to
https://www.nasdaq.com/press-release/biogen-to-expand-biosimilars-portfolio-and-gain-access-to-additional-markets-through
https://www.nasdaq.com/press-release/biogen-to-host-investor-webcasts-from-clinical-trials-on-alzheimers-disease-ctad
https://www.nasdaq.com/press-release/biogen-and-alkermes-announce-fda-approval-of-vumeritytm-diroximel-fumarate-for-0
https://www.nasdaq.com/press-release/biogen-and-alkermes-announce-fda-approval-of-vumeritytm-diroximel-fumarate-for
https://www.nasdaq.com/press-release/thinking-about-buying-stock-in-aurora-cannabis-biogen-boston-scientific-lyft-or-wells
https://www.nasdaq.com/press-release/biogen-plans-regulatory-filing-for-aducanumab-in-alzheimers-disease-based-on-new
https://www.nasdaq.com/press-release/biogen-and-samsung-bioepis-to-present-data-for-infliximab-and-adalimumab-biosimilars
https://www.nasdaq.com/press-release/landmark-nurture-study-of-infants-with-spinal-muscular-atrophy-sma-treated-pre
https://www.nasdaq.com/press-release/biogen-announces-leadership-update-2019-10-01
https://www.nasdaq.com/press-release/interferon-beta-treatments-including-plegridyr-peginterferon-beta-1a-and-avonexr
https://www.nasdaq.com/press-release/biogen-advances-spinal-muscular-atrophy-sma-clinical-research-with-new-study
https://www.nasdaq.com/press-release/biogen-ranked-1-biotechnology-company-on-dow-jones-sustainability-world-index-2019-09
https://www.nasdaq.com/press-release/sp-500-buybacks-decline-significantly-in-q2-2019-expenditures-still-remain-higher
https://www.nasdaq.com/press-release/new-research-demonstrate-biogens-continued-commitment-to-improve-care-of-patients
https://www.nasdaq.com/press-release/new-data-presented-at-ectrims-reinforce-long-term-benefits-of-tecfiderar-dimethyl
https://www.nasdaq.com/press-release/diroximel-fumarate-demonstrated-significantly-improved-gastrointestinal-tolerability
https://www.nasdaq.com/press-release/wedbush-securities-senior-vice-president-equity-research-laura-chico-ph.d.-initiates
https://www.nasdaq.com/press-release/alzheimers-clinical-trials-consortium-selects-elenbecestat-and-ban2401-upcoming-0
https://www.nasdaq.com/press-release/alzheimers-clinical-trials-consortium-selects-elenbecestat-and-ban2401-upcoming
https://www.nasdaq.com/press-release/biogen-continues-advance-innovation-sma-new-data-adults-and-infants-be-presented-mda
https://www.nasdaq.com/press-release/financialbuzzcom-market-recap-week-ending-march-22nd-2019-2019-04-21
https://www.nasdaq.com/press-release/biogen-enters-agreement-sell-its-large-scale-biologics-manufacturing-site-hillerod
